Site Map

Pages

• Prizes and Scholarships
• Home
• PAGANZ Community
• Events
• Gallery
• Contact
• Privacy Policy
• A History of Pharmacometrics in New Zealand and Australia
• Create an account
• Login
• Newsletters & Updates
• Submit Abstract
• My abstracts
• Revise abstract
• Profile
• Population Approach Q&A Discussion Board
• PAGANZ Inc Committee
• PAGANZ Incorporated Society Members
• PAGANZ Incorporated Society Application
• Logo
• PAGANZ Inc Rules
• PAGANZ Incorporated Committee Member Nomination
• Bank Details
• Auckland 2019
  • Program
  • Participants
• Melbourne 2018
  • PAWS Program – Beginner & Intermediate
  • PAGANZ Program
• Adelaide 2017
  • Adelaide and South Australia Information
  • PAGANZ Program
  • PAWs Program
  • Participants
• Melbourne 2015
  • Participants
  • PAWs Program
  • PAGANZ Program
• Dunedin 2014
  • Dunedin and Otago Information
  • Participants
  • Program
• Brisbane 2013
  • Brisbane and Queensland Information
  • Program
  • Participants
• Melbourne 2012
  • Program
  • Participants
• Auckland 2011
  • Program
  • Participants
• Adelaide 2010
  • Program
  • Participants
• Newcastle 2009
  • Program
  • Participants
• Dunedin 2008
  • Program
  • Participants
• Singapore 2007
  • Program
  • Participants
• Auckland 2006
• Queensland 2005
• Adelaide 2004
• Sydney 2003
• Melbourne 2002
• South Africa 2002 PAGANZA
• Christchurch 2001
• Brisbane 2000
• Site Map
• Auckland 1999

Abstracts

• External evaluation of population pharmacokinetic models of tacrolimus in adult heart transplant recipients
• Quantifying the Dose-Response of Unfractionated Heparin Using a System Pharmacology Model of Coagulation
• A Population Pharmacokinetic Model of Phenobarbitone in Neonates to Determine Oral Bioavailability and Facilitate Individualised Dosing
• PBPK modeling for lindane across different species
• Modelling of delivery kinetics of gentamicin administered through umbilical long lines
• A Population Pharmacokinetic Study of Caffeine Citrate in Chinese Premature Neonates
• Future work in Auckland: procalcitonin in healthy and infected neonates to inform PKPD disease progression modelling
• Parameter Analysis for PBPK Model for Enalapril
• Simulations to explore studies of propofol infusions in neonates and infants
• PAGANZ Workshop: CellML and OpenCOR
• Twenty Years of PAGANZ
• Extrapolation of acetaminophen PK models from adults to paediatricians
• How many NMLE articles are published in higher Impact Factor clinical journals?
• Pharmacodynamic effect of evogliptin on bone metabolism in healthy menopausal women
• Combining PK and PD data; a 20 year perspective
• Implementation of an approximate input forcing function for modelling single tissues in the Open Pharmacology Suite
• From the First to the NextDose: My journey through 20 years of PAGANZ
• The Influence of Genotype on Warfarin Dose Predictions
• A Population Pharmacodynamic Study of Apnea of Prematurity and the Effect of Caffeine Citrate in Chinese Premature Neonates
• Evaluation of study designs to test the intact nephron hypothesis
• Analyzing endpoints with many ordered categories: theory and applications
• Predictive performance of a Bayesian forecasting software for tacrolimus in adult heart transplant
• An ePKPD model for sodium nitroprusside in adolescents
• PKPD Explorations Using Paracetamol; 20 years on
• Evaluation of the fingerprint profiles of the cannabinoid-1 receptor signalling via a kinetic modelling approach
• Pharmacometric modelling of deuterium exposure in breastfeeding mother-infant pairs for the determination of exclusive breastfeeding practice
• Investigating the pharmacokinetics of snake venom – a cocktail of toxins
• A mathematical model for warfarin reversal using vitamin K
• A quantitative systems pharmacology model for glutathione depletion during paracetamol overdose
• An extension of Janmahasatian’s fat-free mass model to incorporate differences due to ethnicity
• Dose banding- weighing up benefits vs risks
• A Regression Approach to Visual Predictive Checks for Population Pharmacokinetic and Pharmacodynamic Models
• Vancomycin dose optimisation in patients receiving high-flux haemodialysis
• Mechanism-based modelling to optimise piperacillin plus tobramycin combination dosage regimens against Pseudomonas aeruginosa for patients with altered pharmacokinetics
• Optimal design for determination of AUC with no prior pharmacokinetic knowledge
• A bounded integer model for rating and composite scale data
• Covariate selection methods comparison, introducing the feature of a prior
• Combined population pharmacokinetic model of tenofovir and emtricitabine and their active intracellular metabolites in HIV Patients from the ANRS 134-COPHAR 3 trial
• Meta-analysis of snake venom pharmacokinetics in humans
• Development of a model to predict lean liver volume (LLV) for use in scaling drug clearance
• Assessing the completeness of a QSP model for azathioprine metabolism
• Population pharmacokinetics of gentamicin in paediatrics: quantifying covariate-parameter relationship using the full random effects modelling (FREM) approach
• The Relationship Between Busulphan AUC and the Incidence of Sinusoidal Obstruction Syndrome in Haematopoietic Stem Cell Transplants.
• Study designs for renal drug studies
• Total and unbound mycophenolic acid pharmacokinetics before and after kidney transplantation
• Performance of a Theory-Based Mechanistic Model for Predicting the Target Dose of Warfarin
• ANZDATA: Pharmacology based time to event analysis for death and renal transplant failure
• Pharmacokinetics and metabolism of dabrafenib and trametinib in BRAF V600E/K metastatic melanoma
• A population pharmacokinetic model for 51Cr EDTA to estimate renal function
• Evaluation of assumptions underpinning pharmacometric models
• Kinetic modelling of ligand mediated internalisation
• Linearisation and automatic scale reduction of bone biology QSP models for data-driven analyses
• An approach to evaluating mass and energy balance of pharmacokinetic systems using bond graph theory
• Alphaxalone Anaesthesia PKPD
• Internal Deterministic Identifiability of PK and PKPD Models
• Application of relative forgiveness using clinically observed adherence profiles
• Solutions for nonlinear ordinary differential equations in pharmacokinetic-pharmacodynamic systems
• Population pharmacokinetic and pharmacodynamic properties of OZ439 in healthy volunteers and patients with falciparum and vivax malaria
• NextDose – A web based dosing tool – Development version 2017
• Systems Pharmacology – Learning from GAVamycin
• Performance of estimation methods in modelling the kinetics of respiratory virus infection
• Identifiability analysis of empirical models used for quantifying “biased” ligands
• Population in vitro-in vivo correlation model linking gastrointestinal transit time, pH with the in vivo disposition kinetics of itraconazole
• Assessing the predictive performance of an interactive application to dose adjust voriconazole
• Development of an Interactive Tool to Explore Doses & Sample for Paediatric Trials
• Influence of study design on choice of the allometric exponent
• Improving gentamicin dosing in paediatric oncology patients
• Mechanism-based PK/PD modelling approach to optimise combination dosage regimens against multidrug-resistant clinical isolates of Pseudomonas aeruginosa and in-vivo evaluation in a murine thigh infection model
• Understanding the sensitivity of international normalized ratio (INR) to variations in clotting factor levels
• Population Pharmacokinetic Model of Doxycycline Plasma Concentrations – Pooled Study Data
• Comparison of Non-Compartmental and Mixed Effect Modelling Methods for Establishing Bioequivalence for the Case of Two Compartment Kinetics and Censored Concentrations
• Infliximab maintenance dosing in inflammatory bowel disease: an example for in silico assessment of adaptive dosing strategies
• Busulfan Target Concentration Intervention Audit and Model Evaluation
• Application of an in silico knockout model for gastrointestinal absorption of ketones using a systems pharmacology approach
• A suggestion for determining systematic bias when measuring predictive performance
• Population modelling of influenza viral kinetics, immune response, symptom dynamics and the effect of oseltamivir
• The hazards of acquiring Aspergillus positive culture in children with cystic fibrosis
• The effects of polypharmacy and Drug Burden Index on transitions in cognitive function and death: the CHAMP study
• Population pharmacokinetic modelling of itraconazole and hydroxyl-itraconazole for oral Lozanoc® and Sporanox® capsule formulations in healthy volunteers in fed and fasted state.
• Allopurinol dosing in patients with renal impairment
• Population modelling of lithium in paediatric patients with bipolar disorder: implications for dosing
• Modeling of blood pressure lowering effect for co-administration of valsartan and amlodipine
• Quantitative Assessment of Nocturia Patient’s Urination Pattern and Drug Treatment Effects using a Joint Ordered Categorical Model
• Mechanism-based pharmacodynamic modelling approach to optimise synergistic carbapenem plus aminoglycosides combinations to combat carbapenem-resistant Acinetobacter baumannii
• A repeated time-to-event analysis of onset and offset times of sildenafil erectile response
• Pharmacokinetic modelling of enterohepatic circulation of mycophenolic acid in Malaysian lupus nephritis patients
• Automated proper lumping for the simplification of linear systems
• Impact of high-flux haemodialysis on the probability of target attainment for amoxycillin/clavulanic acid combination therapy
• A Systematic Evaluation of Single Metrics in Discriminating Changes in Rheumatoid Arthritis Disease Activity
• A population PKPD model for neutropenia during Hyper-CVAD chemotherapy in non-Hodgkin lymphoma
• Time-to-event model of leflunomide cessation due to toxicity in rheumatoid arthritis patients: Genetic polymorphism of CYP1A2 but not total or free teriflunomide concentrations is associated with cessation.
• Redefining normal variability of drug disposition
• Characterising the transmission dynamics of Acinetobacter baumannii in intensive care units using hidden Markov models
• Model-based estimation of anticholinergic burden
• Evaluation of NONMEM 7.3.0 and Monolix 4.2.2 by Parametric Bootstrap
• Integrating a PKPD computer simulation in the BPharm course
• SimPharm v2.0: A patient-simulation based clinical pharmacology teaching tool
• The influence of CYP2C9 and VKORC1 genotype on the predictive performance of a Bayesian forecasting method for warfarin therapy
• Model based longitudinal meta-analysis of FEV1 in COPD trials
• The use of a population approach in paraquat toxicokinetic/dynamic study
• Fentanyl for pain management in cancer patients – Population PK design
• Comparing Dosage Adjustment Methods for Once Daily Tobramycin in Children with Cystic Fibrosis
• Population pharmacokinetics of colistin and its prodrug colistin methanesulfonate following intravenous and pulmonary dosing in sheep
• Individualisation of Leflunomide Dosing in Rheumatoid Arthritis Patients : Development of a Semi-Physiologically Based Pharmacokinetic Model
• Oseltamivir dosing optimisation in patients treated with automated peritoneal dialysis
• ISoP Lecture 2014: What have models ever done for you?
• Estimating the relative potencies of an anticholinergic medicine: A methodological view point
• Development of a criterion to quantify forgiveness
• Population pharmacokinetic model for D-β-Hydroxybutyrate following ketone monoester ingestion
• Simplification of a pharmacokinetic model for red blood cell methotrexate disposition
• ISoP Lecture 2013: “Broadening the Impact” – Identifying Some Novel Clinical Applications of Pharmacometrics Research
• Semi-mechanistic PKPD model of thrombocytopenia characterizing the effect of a new histone deacetylase inhibitor (HDACi) in development, in co-administration with doxorubicin.
• Application of Item Response Theory to ADAS-cog Scores Modelling in Alzheimer’s Disease
• Weight-HbA1c-Insulin-Glucose (WHIG) Model for long term disease progression of Type 2 Diabetes
• Modelling analgesia-concentration relationships for morphine in an experimental pain setting
• Pharmacokinetics of Phenobarbitone in Neonates – A Population Model Based on Routine Therapeutic Drug Monitoring Data
• Can literature models describe the neutropenic time course produced by hyper-CVAD chemotherapy in non-Hodgkin lymphoma?
• Exposure-Response Relationship to Assess the Risk of Neutropenia in Patients With Hepatocellular Carcinoma Treated with Tivantinib
• Voriconazole Population Pharmacokinetics
• Application of Population Modelling to Improve the Estimation of Drug Withdrawal Times in Racehorses
• Bayesian Forecasting of Ribavirin in Hepatitis C patients: Population model and validation.
• Mechanism-based modelling and sequential dosing to elucidate subpopulation synergy for antibiotic combinations
• Modeling of glucose absorption
• Identification of continuous covariate relationships
• A Review of Population Pharmacokinetic and Pharmacodynamic Studies of Mycophenolate in Autoimmune Disease Patients
• Population pharmacokinetics of vancomycin in orthopaedic patients
• Identifiability of Population Pharmacokinetic-Pharmacodynamic Models
• Relating intracellular methotrexate polyglutamate concentrations in red blood cells with clinical response in rheumatoid arthritis
• Comparison of the probability of target attainment (PTA) of anidulafungin for antifungal prophylaxis against Candida species
• Evaluation of methods to handle nuisance covariates that are non-ignorable
• Concordance between criteria for covariate model building
• Development of a simplified mathematical model of the human physiome – An application relating to the cardiovascular system
• Investigations of the representation of covariate changes in NONMEM
• Using a Bayesian Modelling Approach with Balanced Informative Prior to Develop a Optimal Paediatric Dosing Paradigm using Scarce PK Data
• Population pharmacokinetic modelling of fentanyl for pain management in cancer patients
• Busulfan pharmacokinetics in neonates, infants, children and adults
• Paracetamol and diclofenac additive effects after tonsillectomy
• Mechanism-based modelling of antibiotics to optimally cure patients and prevent resistance: progress, gaps, and future perspectives
• The design of a pharmacokinetic study of Intranasal Fentanyl
• Treatment of malaria: from drug discovery to optimisation of current therapies.
• Population Modelling of Vildagliptin as an Inhibitor and Substrate of Dipeptidylpeptidase IV and its Effects on Glucagon-Like Peptide 1, Glucose, and Insulin
• Development and application of a pharmacokinetic model for the glycation of albumin
• Optimal designs for pharmacokinetic-pharmacodynamic studies of dihydroartemisinin following oral artesunate
• Mechanism-based population modelling of dihydoartemisinin pharmacodynamics in murine malaria
• Assessment of vancomycin dosing regimens in Intensive Care Unit patients with impaired renal function
• A model for maturation of milrinone clearance from prematurity to adulthood
• Which matrix is the most reliable to judge the inclusion of covariates: reduction of unexplained parameter variability, increase in explained parameter variability or change in OFV?
• Pharmacokinetics of high-dose methotrexate in children with cancer: A mechanism-based evaluation of clearance prediction
• A clinical trial incident: Why simple PK is sometimes not so simple
• Prediction correction: quick fix for VPC misdiagnosis in a tacrolimus popPK model
• A model for fat free mass in humans from very premature neonates to young adults
• NextDose – A web based collaborative tool for dose individualisation
• What is the between cycle variability in methotrexate clearance?
• The pharmacokinetic profile of intravenous paracetamol in adult patients undergoing major abdominal surgery: A population analysis
• A reduction in between subject variability is not mandatory when adding a new covariate
• Evaluation of a Bayesian dose-individualisation method for enoxaparin
• Adaptive PD-optimal design of a pilot study for a clotting time test for enoxaparin
• Dose Correction for the Michaelis-Menten Approximation of the Target – mediated Drug Disposition Model
• Pharmacokinetics of methotrexate in red blood cells
• What is the best dosing regimen for allopurinol in patients with renal impairment?
• Population Pharmacokinetic Analysis of Ropivacaine and its Metabolite PPX from Pooled Data in Neonates, Infants and Children
• Meta-modelling
• Generalisation of T-optimality for discriminating between competing models – an application to paracetamol overdose
• Initial exploration of numerical methods for fitting models to PK data
• Design of pharmacokinetic studies for latent covariates
• Development of a Mechanism-Based Model for the Pharmacodynamics of Daptomycin against Methicillin Resistant Staphylococcus aureus (MRSA)
• The effect of surgery on the glucuronidation and sulphation of paracetamol
• Modelling red blood cell data
• Utilising prior literature population models to inform clinical practice – a dosing regimen for immediate N-acetyl cysteine treatment of paracetamol overdose
• Identification and initial evaluation of a prototype clotting time test for enoxaparin
• Antibiotic Dosing Calculator in Neonates and Children Trial
• Population Pharmacokinetics of Paracetamol in Overdose in a Single Patient
• Dexmedetomidine Hemodynamics in Children after Cardiac Surgery
• Modeling of non-stationary RBC survival: Effect of erythropoietin on RBC mortality vs. production in rats.
• Quantifying Disease Progress with Inactive Treatments in Multiple Parkinson
• Methods to Determine Optimal Sampling Windows for Nonlinear Mixed Effects Models
• Optimal designs for population pharmacokinetic studies of the partner drugs administered with artemisinin derivatives
• Development of fluconazole dosage guidelines in critically ill patients receiving continuous venovenous hemodiafiltration
• fit4NM : A tool for NONMEM users
• The use of PKPD simulations to inform the rational use of medicines in clinical practice: the case of simvastatin circadian dosing
• What is needed for a dosing calculator?
• Predicting Weight Using Postmenstrual Age
• Is Morphine Clearance Predictable in Humans?
• Missing data
• Population Pharmacokinetic-Pharmacodynamic Modeling: When Modeling Meets Reality
• Population pharmacokinetics of midazolam in critically ill septic patients
• Population pharmacokinetic and pharmacodynamics analysis of lipid emulsion propofol in pediatric patients
• Population Pharmacokinetics of Gentamicin in Saudi Newborns during the 1st Week of Life
• Population Pharmacokinetics of Colistin Methanesulfonate and Formed Colistin in Critically-Ill Patients from a Multi-Center Study Provide Dosing Recommendations for Patients
• Missing data – the problem of silent evidence
• Statisticians and Pharmacometricians: What can they learn from each other?
• Population pharmacokinetics of meropenem in burn patients
• Pharmacodynamics of venlafaxine in overdose
• Identifiability of random effects parameters in mixed effects models
• Adaptive Bridging Studies in Pharmacokinetics
• Online dose calculation tool for determining dosing regimens in the very young
• Predicting the antimalarial effect of artesunate-mefloquine combination therapy using a mechanistic pharmacokinetic-pharmacodynamic model
• Optimal designs for warfarin INR monitoring
• A mathematical model for the effect of malaria on arginine catabolism in endothelial cells
• Population Pharmacokinetics of Vancomycin in Premature Malaysian Neonates: Identification of Predictors for Dosing Determination in the First Month of Life
• Evaluation of an optimal design for examining melphalan pharmacokinetics in patients with multiple myeloma
• A population PK-PD model of unbound Docetaxel in patients with liver impairment and identification of potential covariates for initial dosage adjustment
• Design of survival studies for red blood cells
• Optimal design of time-to-event models with an emphasis on dropouts in disease progression studies
• Population pharmacokinetics of total and unbound melphalan in patients with multiple myeloma
• Developing a model for estimating lean body weight in children
• Can PBPK Models Predict Post-Mortem Redistribution?
• Pharmacokinetics of Tramadol in Human Neonates, Children and Adults and in Adult Rats, Cats, Dogs, Goats and Horses
• Population pharmacokinetics of oxypurinol in patients with gout receiving allopurinol
• Optimal designs for population pharmacokinetic studies of a drug with large assay variability for patients with restrictive sampling schedules
• Novel diagnostics for assessing fit of logistic regression models
• The population pharmacokinetics of propofol: a meta-analysis of studies available from the OpenTCI Initiative
• Pharmacokinetics of Chloroquine in Pregnant and Non-pregnant Women in Papua New Guinea
• The Influence of Study Design on Identification of True Parameter-Covariate Relationships
• Risk of QTc Interval Prolongation and Torsades de Pointes (TdP) with Amisulpride
• A nonlinear mixed effects model to characterise lamivudine absorption and distribution
• The Effect of Study Design on Pharmacokinetics in Patients with Impaired Renal Function
• Does the use of Lean Body Weight (LBW) in a modified Cockcroft-Gault (C-G) equation provide a better prediction of gentamicin clearance?
• Understanding intranasal fentanyl for acute pain treatment in children: randomized controlled trials or population pharmacodynamic studies?
• Non Linear Deconvolution
• Robust D-optimal Design of Nonlinear Fixed Effects Pharmacokinetic Model
• Population pharmacokinetics of mycophenolic acid in children and young people undergoing bone marrow and solid organ transplantation
• Correlation in the absorption of lamivudine and zidovudine when administered as a fixed-dose combination tablet
• A case for routine monitoring of enoxaparin treatment
• Recirculatory Modelling of Nasal Fentanyl in Man
• Pharmacokinetics of Ethanol in the Presence of Methanol
• Population Pharmacokinetics Of Gentamicin In Very Premature Neonates
• An assessment of methods for modelling regional pharmacokinetics – pooled data, pooled parameter estimates or NONMEM?
• Mechanism-based Pharmacodynamic (PD) Modeling of Phenotypic Tolerance in Pseudomonas aeruginosa for Ceftazidime
• Lean body weight versus total body weight for propofol dosing
• A model of coagulation disturbances in snake bites
• Population pharmacokinetics of phenobarbitone administered as oral rescue therapy in children with refractory status epilepticus
• The evaluation of an individualised dosing strategy derived from population PK modelling and simulation
• Lean Body Weight as a Robust Size Descriptor for Quantifying the Impact of Body Composition on Drug Clearance
• Handling Correlated Variables
• Population pharmacokinetics of acyclovir in children with malignancy
• What to do about missing dosage history?
• Optimal design for drug interaction studies – Beyond the criss-cross design
• Modeling Diverse Anti-Diabetic Drug Effects Using Indirect Response Models: Review
• Simulation of an optimal pharmacokinetic and pharmacodynamic amikacin dosing regimen for neonates
• Mechanistic Modeling of Magnetically Marked Extended Release Formulation of Felodipine
• Handling data below the limit of quantification in mixed effect models
• When Missing Does Not Mean Lost [OED]
• Population pharmacokinetics of melphalan in myeloma patients undergoing an autograft
• Pharmacokinetics of L-arginine after intravenous infusion in adults with moderately severe malaria
• Preclinical Population PK/PD of TGF beta RI Kinase inhibitor for Cancer
• Lean Body Weight versus Total Body Weight as a Covariate for Clearance
• Normalized prediction distribution errors for the evaluation of nonlinear mixed-models
• Tobramycin in paediatric CF patients – TCI or
• Development of a sufficient design for parameter estimation of fluconazole population pharmacokinetics in HIV patients
• Population pharmacokinetic analysis of morphine in opioid dependent and control subjects
• Comparison of different diagnostic criterion to evaluate nonlinear mixed-effects models
• Optimal Designs of Studying Bioimpedance – Design for Nonlinear Mixed Effects Models
• Nonlinear Mixed Effects Modeling of the Steady-State Pharmacokinetics (PK) of Tipranavir/Ritonavir 500/200 mg bid (TPV/r) for Adult Healthy Volunteers and HIV+ Patients
• Different ways of incorporating data below the quantification limit in datasets for parameter estimation
• Population Pharmacokinetics of Amikacin in Very Premature Malaysian Neonates
• Maximum likelihood estimation in nonlinear mixed effects models with the SAEM algorithm
• Population Pharmacokinetics of Oral and Intravenous Caffeine in Extremely Premature Neonates
• Population Pharmacokinetics of Phase 1/2a Data After Oral Tablet Administration of Maraviroc